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To determine the role of telomere dysfunction and
telomerase reactivation in generating pro-onco-
genic genomic events and in carcinoma progres-
sion, an inducible telomerase reverse transcriptase
(mTert) allele was crossed onto a prostate cancer-
prone mouse model null for Pten and p53 tumor
suppressors. Constitutive telomerase deficiency
and associated telomere dysfunction constrained
cancer progression. In contrast, telomerase reacti-
vation in the setting of telomere dysfunction allevi-
ated intratumoral DNA-damage signaling and
generated aggressive cancers with rearranged ge-
nomes and new tumor biological properties (bone
metastases). Comparative oncogenomic analysis
revealed numerous recurrent amplifications and
deletions of relevance to human prostate cancer.
Murine tumors show enrichment of the TGF-b/
SMAD4 network, and genetic validation studies
confirmed the cooperative roles of Pten, p53, and
Smad4 deficiencies in prostate cancer progression,
including skeletal metastases. Thus, telomerase
reactivation in tumor cells experiencing telomere
dysfunction enables full malignant progression and
provides a mechanism for acquisition of cancer-
relevant genomic events endowing new tumor bio-
logical capabilities.896 Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc.INTRODUCTION
Many genome instability mechanisms can contribute to somatic
events present in human cancer genomes, particularly epithelial
cancers (DePinho, 2000; Storchova and Pellman, 2004).
Genetic studies illuminated a key role for telomere dysfunction
in driving cancer initiation and shaping cancer genomes (Artandi
and DePinho, 2010). When combined with p53 mutation, which
deactivates p53-dependent DNA-damage signaling (Chin et al.,
1999), telomere dysfunction engenders DNA double-strand
breaks that produce nonreciprocal translocations, amplifica-
tions, and deletions; this process promotes epithelial carcino-
genesis (Artandi et al., 2000; O’Hagan et al., 2002).Telomere
dynamics contribute to human epithelial cancers as evidenced
by coincidental telomere erosion, anaphase bridging, and chro-
mosomal instability in early stages of carcinogenesis in the
colon (Rudolph et al., 2001), prostate (Meeker et al., 2002),
breast (Chin et al., 2004), and pancreas (Feldmann et al.,
2007). Human carcinoma sequencing has provided additional
evidence that a period of telomere dysfunction generates chro-
mosomal rearrangements (Stratton et al., 2009). In human
prostate cancer, cancer cells possess shorter telomeres (Som-
merfeld et al., 1996) as a result of telomere erosion early in
disease evolution (Meeker et al., 2002; Vukovic et al., 2003).
Curiously, prostate cancers do not arise spontaneously in
mice with telomere dysfunction and p53 deficiency (Artandi
et al., 2000). Although casting uncertainty as to the relevance
of telomeres in prostate cancer pathogenesis and in shaping
its complex genome, it is also possible that mice may not
possess key genetic or environmental factors required to
harness telomere dysfunction as a mechanism to promote the
neoplastic process in the prostate.
Whereas telomere dysfunction serves to drive early stages of
cancer development, subsequent telomerase activation and
restoration of telomere function appear to be critical for full
malignant progression. This hypothesis is supported by frequent
activation of telomerase in diverse human cancers (Shay and
Wright, 2006) and enablement of enforced TERT in oncogene-
induced malignant transformation of human primary cells
(Hahn et al., 1999). Accordingly, low telomerase activity in
normal prostate tissues is markedly elevated in human prostate
tumors (Kallakury et al., 1997; Lin et al., 1997; Sommerfeld et al.,
1996; Koeneman et al., 1998; Zhang et al., 1998).
Genetic events associated with human prostate cancer, the
most common cancer and second leading cause of cancer death
in American men (Jemal et al., 2010), include ETS family member
translocation (Tomlins et al., 2005; Rubin, 2008) and (epi)genetic
alterations of PTEN, p27Kip1, NKX3.1, c-MYC, FGFRs, EZH2/
MIR101, p53, SMAD4, among others (Li et al., 1997; Guo et al.,
1997; Abate-Shen et al., 2008; Jenkins et al., 1997; Acevedo
et al., 2009; Ding et al., 2011). Genomic analysis of human pros-
tate cancers has revealed numerous recurrent amplifications
and deletions (Taylor et al., 2010), pointing to the existence of
many new prostate cancer-relevant genes. Identification and
validation of these genes in amplifications and deletions are
challenged by involvement of a significant fraction of the
genome, marked intratumoral heterogeneity, and paucity of
human cell-based model systems. In this regard, comparison
of human and mouse cancer genomes has proven highly effec-
tive in facilitating cancer gene discovery (Kim et al., 2006; Zender
et al., 2006), particularly inmousemodels with telomere dysfunc-
tion that promotes regional amplifications and deletions of
cancer-relevant loci (Maser et al., 2007; O’Hagan et al., 2002).
Here, we sought to understand the role of telomere dysfunction
and telomerase reactivation in prostate cancer progression and
in generating genomic events that may promote new tumor bio-
logical properties of this common malignancy.
RESULTS
Telomerase Reactivation in Genome-Unstable Mouse
Prostate Cancer Model Drives Metastatic Progression
In this study, we employed two distinct telomerase reverse
transcriptase (mTert) alleles to study how telomere dysfunction
and subsequent telomerase reactivation influence the genomes
and biology of prostate cancer. The first allele is a conventional
mTert knockout resulting in constitutive telomerase deficiency
and telomere dysfunction upon successive generational
mTert/ intercrosses. The second allele is a novel inducible
mTert knockin containing an intronic Lox-Stop-Lox cassette
(LSL) (Figure 1A), and upon Cre-mediated excision of LSL,mTert
is re-expressed under endogenous control mechanisms.
Mice possessing probasin (PB) promoter-driven Cre trans-
gene (Wu et al., 2001) and p53/pten conditional knockout alleles
(hereafter PB-Pten/p53) characteristically develop locally inva-
sive nonmetastatic prostate adenocarcinoma with high pene-
trance and short latency (Chen et al., 2005). Alleles were
backcrossed a minimum of four generations onto C57Bl/6.Upon successive generational intercrosses of LSL-mTert mice,
late generations show classical constitutional signs of telomere
dysfunction, including reduced body weight (Figure 1D), wide-
spread organ atrophy (Figures 1B and 1E), diminished prolifera-
tion, and increased apoptosis in highly proliferative tissues
(Figures 1C and 1F), among other phenotypes as reported previ-
ously (Lee et al., 1998). Of note, PB-driven Cre expression is
restricted to prostate epithelium and becomes active at sexual
maturity. Thus, Cre-mediated deletion of LSL and mTert re-
expression (telomerase reactivation) can occur in prostate
epithelium experiencing telomere dysfunction.
PB-Pten/p53 alleles were carried through successive genera-
tional mating of LSL-mTert mice (Figure S1 available online),
generating ‘‘telomere-intact’’ controls (wild-type and LSL-mTert
heterozygous mice, designated ‘‘G0 PB-Pten/p53’’) and ‘‘telo-
mere dysfunctional’’ experimental mice (third and fourth genera-
tion LSL-mTert, designated ‘‘G3/4 LSL-mTert PB-Pten/p53’’).
In parallel, we generated control and experimental cohorts of
PB-Pten/p53 mice harboring the conventional mTert null allele
(mTert) (Farazi et al., 2006), producing analogous G3/4
mTert/ PB-Pten/p53 to study the impact of telomere dysfunc-
tion only.
Consistent with a previous report (Chen et al., 2005), G0
PB-Pten/p53mice withmTert+/+ ormTert+/ alleles (i.e., without
telomere dysfunction) developed rapidly progressive, locally
invasive prostate adenocarcinomas with 100% penetrance,
whereas G3/4 mTert/ PB-Pten/p53 mice (i.e., experienced
ongoing genome instability due to telomere dysfunction) had
smaller, poorly progressive tumors (Figures 2A–2D). Serial histo-
logical analyses revealed high-grade prostate intraepithelial
neoplasia (HPIN) by age 9 weeks in both cohorts (Figure S2A).
However, most G3/4 mTert/ PB-Pten/p53 tumors failed to
progress beyond HPIN through age 24 weeks (Figures 2C and
2D; Table S1), whereas G0 PB-Pten/p53 tumors evolved to inva-
sive adenocarcinoma by age 24 weeks with 100% penetrance
(Figures 2C and 2D). In comparison, G3/4 LSL-mTert PB-Pten/
p53 mice (i.e., experienced baseline telomere dysfunction prior
to telomerase reactivation at sexual maturity) also initiated with
HPIN by age 9 weeks (Figure S2A), but unlike the G3/4mTert/
mice, they developed bulky lethal tumors by age 24 weeks
(Figures 2A–2D). These observations reinforced the established
role of telomere dysfunction in facilitating cancer initiation yet
constraining full malignant progression (Rudolph et al., 2001;
Gonza´lez-Sua´rez et al., 2000; Chin et al., 1999), whereas telome-
rase reactivation enabled rapidly progressive disease. Impor-
tantly, a new phenotype emerged among some of the G3/4
LSL-mTert PB-Pten/p53 mice that is not observed in the
genome-stable G0 PB-Pten/p53 mice, namely lumbar spine
metastases (5/20, 25%) (Figures 2E, 2F, and S2B). The prostate
cancer origin of these metastases was confirmed by genotype
analysis of Cre-deleted Pten, p53, and LSL sequences (Figures
S2C and S2D; not shown). This new phenotype suggests that
its evolution requires not just a stable genome but antecedent
instability induced by telomere dysfunction.
Next, the impact of telomerase reactivation was assessed in
age-matched prostate tumors from each model. Quantitative
telomere-fluorescence in situ hybridization (FISH) revealed
decreased telomere reserves in G3/4 mTert/ PB-Pten/p53Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc. 897
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Figure 1. A Novel Inducible mTert Knockin Containing an LSL Cassette in the First Intron
(A) LSL-mTert knockin strategy.PB-Cre4-redirected, Cre-mediated recombination removes the LSL cassette in prostate epithelium to restore endogenousmTert
expression.
(B and C) Later generations (G3, G4) of mTert/ PB-Pten/p53 (panel b) or LSL-mTert PB-Pten/p53 alleles (panel c) displayed telomere dysfunction as
demonstrated by decreased testis weight, compared to G0 mTert PB-Pten/p53 (panel a) (B), and increased apoptotic bodies in intestine (C).
(D–F) Quantification of bodyweight (D), testis weight (E), and apoptotic bodies per 100 intestinal crypts (F) of G0PB-Pten/p53 (denoted asG0mTert) (n = 20), G3/4
mTert/ PB-Pten/p53 (denoted as G4mTert/) (n = 31), and G3/4 LSL-mTert PB-Pten/p53 (denoted as G3/4 LSL-mTert) (n = 20) mice (F). Error bars represent
standard deviation (SD), * indicates p < 0.05.
See also Figure S1.samples relative to G0 PB-Pten/p53 samples, whereas G3/4
LSL-mTert PB-Pten/p53 samples showed longer telomere
lengths relative to G3/4 mTert/ PB-Pten/p53 (Figure S3). As
eroded dysfunctional telomeres generate a DNA-damage
response (Takai et al., 2003; d’Adda di Fagagna et al., 2003),898 Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc.functional restoration of telomereswas assessed by examination
of DNA-damage signaling (p53BP1 foci) in the various models.
Strong anti-p53BP1 signal was detected in G3/4 mTert/
PB-Pten/p53 tumor cells and was greatly reduced in G0
PB-Pten/p53 and G3/4 LSL-mTert PB-Pten/p53 tumor cells
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Figure 2. Telomere Dysfunction and Telomerase Impact Prostate Cancer Progression
(A) Gross anatomy of representative prostates at 24 weeks of age.
(B) Quantification of the prostate tumors of G0 mTert (n = 20), G3/4 mTert/ (n = 31), and G3/4 LSL-mTert (n = 20) mice. Error bars represent SD.
(C) Representative H&E sections of the prostate tumors from G0mTert (panel a), G3/4mTert/ (panel b), and G3/4 LSL-mTert (panel c) mice at 24 weeks of age.
(D) Quantification of locally invasive prostate tumors of G0 mTert (n = 20), G3/4 mTert/ (n = 31), and G3/4 LSL-Tert (n = 20) mice at 24 weeks of age.
(E) H&E sections of the prostate tumors of G4 LSL-Tert in spinal bone at 24 weeks of age.
(F) Quantification of prostate tumors with spread lumbar spine in G0 mTert (n = 20), G3/4 mTert/ (n = 31), and G4 LSL-Tert (n = 20) mice.
See also Figure S2 and Table S1.(Figures 3A and 3B; n = 3 each). Correspondingly, there was
markedly increased apoptosis and decreased proliferation in
G3/4 mTert/ PB-Pten/p53 tumor cells compared with G0
PB-Pten/p53 and G3/4 LSL-mTert PB-Pten/p53 controls
(Figures 3C–3E). Thus, telomerase activation alleviates telomere
dysfunction checkpoints in G3/4 LSL-mTert PB-Pten/p53
cancers.
Taken together, the molecular and phenotypic characteriza-
tion of these three models demonstrated that telomerase reacti-
vation not only enables the bypass of the progression block
conferred by telomere dysfunction by quelling the DNA-damage
signals but also engenders the acquisition of new tumor biolog-
ical properties (bony tumor growth) not observed in tumors thatdid not experience a period of telomere dysfunction with sub-
sequent telomerase reactivation in their evolution. This thus
provides the first genetic evidence that telomerase reactivation
and genome stabilization are necessary to drive full malignant
progression in epithelial cancers.
Genome Stabilization by Telomerase Reactivation
Selects for Copy Number Aberrations of Human
Relevance
We hypothesized that baseline telomere dysfunction in G3/4
LSL-mTert PB-Pten/p53 cells followed by telomerase reactiva-
tion in the prostate upon sexual maturity at 5–7 weeks of age
(Chen et al., 2005; Wu et al., 2001) would be permissive of theCell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc. 899
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Figure 3. Telomerase Reactivation Maintains Telomere Length and Allows Tumor Cells to Proliferate
(A) Strong telomere dysfunction-induced p53BP1 foci were presented in G3/4 mTert/cells (panel b) but not in G4 LSL-Tert cells (panel c).
(B) Quantification of p53BP1-positive prostate tumor cells. Error bars represent SD for a representative experiment performed in triplicate.
(C–E) Telomere dysfunction-induced apoptosis and blockage of proliferation. Quantification of TUNEL-positive (C), caspase-3 activation-positive (D), and Ki67-
positive prostate tumor cells (E). Error bars represent SD for a representative experiment performed in triplicate.
See also Figure S3.accumulation of genomic events in established tumors. Indeed,
spectral karyotyping (SKY) analyses of G0 PB-Pten/p53 and
G3/4 LSL-mTert PB-Pten/p53 prostate tumors revealed an
increased number of chromosomal structural aberrations in
G3/4 mTert LSL-mTert PB-Pten/p53 tumor samples (n = 5)
relative to G0 PB-Pten/p53 controls (n = 4) (Figures 4A–4C; 3.2
versus 1.0 per 100 chromosomes, respectively, p < 0.05,
t test). These cytogenetic aberrations included multicentric
chromosomes, nonreciprocal translocations (NRTs), in addition
to p-p, p-q, and q-q chromosome arm fusions involving homol-
ogous and/or nonhomologous chromosomes (Figure 4B).
Telomere dysfunction and the associated bridge-fusion-
breakage process are known to create DNA double-strand
breaks, leading to regional amplifications and deletions at the
sites of breakage (O’Hagan et al., 2002). Under biological selec-
tion, this process can result in copy number aberrations (CNAs)
at cancer-relevant loci (Maser et al., 2007; O’Hagan et al., 2002).
Prompted by this, we performed array-based CGH and tran-
scriptional profile analyses of 18 G3/4 LSL-mTert PB-Pten/p53
tumors. Compared to matched germline DNA in each case,
94 recurrent somatic copy number alterations (sCNAs) were
defined by MCR analysis, encompassing 2,183 amplified and
3,531 deleted genes (Figure S4; Table S2).
To assess human relevance of these murine sCNAs, we used
GISTIC2 (Beroukhim et al., 2007) to analyze genome-wide copy900 Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc.number profiles of 194 human prostate tumors (Taylor et al.,
2010); this defined 55 recurrent focal sCNAs and 10 recurrent
chromosomal arm-level gains or losses (Figure S4). Cross-
species comparisons by orthologs revealed that 22 of the 94
murine sCNAs harbored synteny to either focal or broad sCNAs
in humans. Consistent with previous studies, resident genes
(300 amplified genes and 441 deleted genes) in these syntenic
sCNAs were indeed significantly enriched for cancer-relevant
genes (Figure S4; Table S2). In particular, one of the cross-
species-conserved CNAs involving mouse chromosome 15
and human chromosome 8 was notable for high recurrence in
both species (mouse: 12/18, 67% and human: 43/194, 22%)
(Table S2; Figure 4D). This syntenic region contains the prostate
cancer-relevant MYC oncogene as well as other known cancer
genes not previously implicated in prostate cancer, such as
WNT pathway regulator FDZ6 (Table S2).
Recognizing that notall genes resident in sCNAsaredrivers,we
next implemented a series of integrative analyses (as outlined in
Figure S4) designed to cull passengers. Briefly, for genes resident
in regions of syntenic amplifications or gains, we prioritized those
with copy number-correlated expression in mouse and human
samples; for genes in regions of loss, we prioritized those with
nonsynonymous mutations documented in COSMIC or in NCBI
PubMed, as well as evidence of promoter DNA hypermethylation
in the published literature (Forbes et al., 2011; Ongenaert et al.,
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Figure 4. Oncogenomic Alterations that Occur in G3/4 LSL-mTert Prostate Tumors
(A) Representative SKY images from metaphase spreads from G0 (panel a) and G3/4 (panel b) prostate tumors.
(B) Quantification of cytogenetic aberrations (recurrences) detected by SKY in G0 mTert (n = 4) and G3/G4 LSL-mTert (n = 5) prostate tumors. Error bars
represent SD.
(C) Quantification of cytogenetic aberrations (recurrences) detected by SKY in G0 mTert (green) and G3/4 LSL-mTert (purple) prostate tumors.
(D) Recurrence plot of CNAs defined by aCGH for 18 mouse prostate tumors. The x axis shows the physical location of each chromosome. The percentage of
prostate tumors harboring gains (bright red, log2 > 0.6), losses (green, log2 < 0.3), and deletions (dark green, log2 < 0.6) for each locus is depicted.
See also Figure S4 and Tables S2 and S3.2008). Furthermore, we posit that drivers targeted by sCNAswith
functional consequences aremore likely to be selected for during
progression. Thus, we utilized the expression profile data in
metastatic versus primary tumors from six prostate cancer
cohorts on Oncomine (Lapointe et al., 2004; LaTulippe et al.,
2002; Vanaja et al., 2003; Varambally et al., 2005; Yu et al.,
2004; Holzbeierlein et al., 2004) to define the subset of genes
exhibiting a progression-correlated expression pattern in human;
namely, genes resident in regions of loss in themouse tumors are
downregulated in human metastases compared to primary, or
conversely genes in regions of gains are upregulated in human
metastases. This multidimensional integrative analysis narrowed
our cross-species-conserved gene list down to 228 genes (77
amplified and 151 deleted) (Figure S4; Table S3).
TGF-b/Smad4 Pathway in Prostate Tumors with Bone
Metastasis
As a first step to identify molecular events capable of driving
metastasis to the bone, we asked whether a subset of the above228 candidate genes are subjected to consistent amplification/
deletion in the 14 bone metastases in the cohort reported by
Taylor et al. (2010). Specifically, we interrogated each of the 77
amplified or 151 deleted candidates for evidence that it is more
likely to be amplified or deleted in bone metastasis, respectively.
The resultant 113 gene list (comprising 37 amplified and 76
deleted genes associated with bone metastasis) was then
enlisted into knowledge-based pathway analysis. Interestingly,
TGF-b signaling genes represented the most significantly en-
riched network among the nine significant pathways with false
discovery rate (FDR) < 0.1 (Table S4; Figure S5A). Corroborating
with this pathway analysis result is the observation that Smad4
is encompassed by genomic loss in 2 of the 18 (11%) G3/4
LSL-mTert PB-Pten/p53 tumor genomes, suggesting that
TGF-b signaling and SMAD4 specifically may be targeted during
prostatecancer skeletalmetastasis. This is consistentwith recent
reports on the pathogenetic and prognostic roles of SMAD4 in
human prostate cancer (Ding et al., 2011) and its frequent epige-
netic silencing in advanced disease (Aitchison et al., 2008).Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc. 901
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Figure 5. Codeletion of SMAD4 together with PTEN and p53 Leads to Aggressive Prostate Cancer Progression
(A and B) Log2 ratio of array-CGH plots showing conserved deletion of SMAD4 in both mouse G3/4 LSL-mTert tumor (A) and human prostate tumor samples (B).
The y axis shows log2 of copy number ratio (normal, log2 = 0); amplifications are above and deletions are below this axis; x axis is chromosome position, in Mbp.
(C and D) Log2 ratio of array-CGH plots showing codeletion of PTEN (C) and p53 (D) in that same human prostate sample with the SMAD4 deletion.
(E) Codeletion analysis of PTEN, p53, and SMAD4 in human prostate cancer samples (n = 194). The p value (Fisher’s exact test) = 2.9 3 106 (asterisk).
(F) Survival curves showing significant decrease in life span in PB-Pten/p53/Smad4 (n = 24) (asterisk) compared with PB-Pten/p53 (n = 25) or PB-Pten/Smad4
(n = 44) cohorts by Kaplan-Meier overall cumulative survival analysis (p < 0.0001).
(G) H&E sections of prostate tumors of PB-Pten/p53/Smad4 in spinal bone at age 19 weeks.
See also Figure S5 and Table S4.To genetically validate the above hypothesis, we crossed
a prostate-specific PB promoter-driven Smad4 conditional
knockout allele onto the prostate-specific p53/Pten double null
model (PB-p53/Pten). The rationale for using the prostate-
specific p53/pten knockout model is based on the fact that this
mouse model does not develop bone metastasis, and, in human
prostate cancers (Taylor et al., 2010), loss of SMAD4 as part of
a large regional CNA is frequent (18% = 35/194) and often co-
occurrs with p53 and PTEN loss (Figures 5B–5D) (Figure 5E,
p = 2.9 3 106 by Fisher’s exact test). Consistent with the
genomic data, prostate-specific deletion of all three tumor
suppressors led to a more aggressive tumor phenotype and
shorter overall survival. The median survival time of 17.05 weeks
in Pten/p53/Smad4 was significantly shorter than in Pten/p53902 Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc.(26.3 weeks) or Pten/Smad4 (22.8 weeks) models (Figure 5F;
p < 0.0001, log-rank test). Most importantly, 3/24 (12.5%) of
the triple knockout mice developed spontaneous bone metas-
tasis (Figure 5G).
In summary, pathway analysis of the cross-species-
conserved gene list triangulated with the biological phenotype
in human prostate cancers led to the hypothesis that TGF-b/
SMAD4 signaling is an important driver of bone metastasis in
the context of Pten and p53 deficiencies. Utilizing the combined
Pten/p53/Smad4 GEM model, we demonstrate the new tumor
biological properties (skeletal metastases) of this GEM model
are not present in Pten/p53 or Pten/Smad4 telomere-intact
GEM models. This study establishes, in a genetic manner, that
telomerase reactivation in tumor cells experiencing telomere
dysfunction provides a mechanism for selection of cooperative
events required to progress fully and manifest the tumor biolog-
ical properties governed by such genomic events.
Evolutionarily Conserved, Genomically Altered Genes
Correlating with Bone Metastasis Are Prognostic
in Human
The in vivo genetic experiment above proving a driver role for
Smad4 in bone metastasis suggests that additional genes on
our bone metastasis-associated gene list may have functional
importance as well. As SMAD4 has also been shown to carry
prognostic significance (Ding et al., 2011), we reasoned that
prognostic relevance may serve as a surrogate for biological
importance. As a proof of concept, we focused on the 14 genes
that are represented in the 9 pathways found to be significantly
enriched in the bone metastasis-associated gene list (Table
S4). Specifically, we assessed how robustly these 14 genes
can stratify risk for biochemical recurrence (BCR, defined by
post-surgery PSA > 0.2 ng/ml) among the 140 patients with
outcome annotation (Taylor et al., 2010). Gratifyingly, the overall
risk score based on the 14 gene signature was significantly prog-
nostic of BCRwith a hazard ratio of 13 (p value < 1014, overall C
index = 0.93, see Figure S5B) by multivariate Cox regression
analysis. Further support for these 14 genes as likely drivers of
bone metastasis phenotype derived from the observation that
they provided independent prognostic value to the previously re-
ported 4 gene signature (comprising PTEN/SMAD4/CCND1/
SPP1) derived from the Pten/Smad4 model (Ding et al., 2011),
consistent with the fact that bone metastasis was not observed
in the Pten/Smad4 GEM model (hazard ratio = 8.7, p = 2.16 3
1013, and overall C index = 0.93, see Figure S5C). In particular,
combination of the 14 gene with the 4 gene signature increases
the predictive power of either gene set alone (hazard ratio = 20,
p < 1014, and overall C index = 0.96, see Figure S5D).
Taken together, the prognostic correlation of these 14 genes
represented in the 9 functional pathways enriched in the bone
metastasis-associated gene set provides the correlative
evidence for biological relevance of these genes to human pros-
tate cancers, although their individual contribution and mecha-
nism of action will require further exploration. Additionally, these
results serve as validation of the integrative approaches adopted
by this study, which leverages the clear genotype-phenotype
correlation in model systems with the power of genomic and bio-
informatic analyses to elucidate molecular mechanisms driving
bone metastasis in human prostate cancers.
DISCUSSION
We explored the role of telomere dysfunction and telomerase re-
activation in shaping the genomes and impacting the biology of
prostate cancer. These genetic studies in vivo, together with
human and mouse prostate cancer genomic data, provide
evidence that telomere dysfunction plays a critical role in pros-
tate cancer initiation and progression, permitting acquisition of
and selection for cancer-relevant genomic events upon telome-
rase reactivation. In addition, our studies support the idea that
telomere dysfunction and subsequent telomerase activation
enable evolving cancers to progress fully and acquire new tumorbiological properties including cardinal features of advanced
human prostate cancer.
Finally, comparative oncogenomic analysis of gene copy
number and expression profiles with genotype-phenotype
correlation resulted in identification of genes associated with
progression to bone metastasis, highlighting the potential utility
of this integrative approach for cancer gene discovery in prostate
cancer.
Previous telomere and cytogenetic studies have documented
chromosomal instability and telomere loss in early stage human
prostate cancers (Sommerfeld et al., 1996; Meeker et al., 2002;
Vukovic et al., 2003), implicating this mechanism in driving chro-
mosomal instability and intratumoral heterogeneity in these
emerging malignancies. These findings, along with work in the
telomerase knockout mouse model (Artandi and DePinho,
2010), support a model where telomere dysfunction provides
a mechanism fueling the early acquisition of somatic genomic
events in prostate cancer as well as other epithelial cancers.
Consistent with previous work in other epithelial cancers, we
observed that constitutive telomere dysfunction in the G3/4
mTert/ PB-Pten/p53 model enabled cancer initiation;
however, these malignancies exhibited a constrained progres-
sion phenotype that was associated with activation of DNA-
damage signaling and increased apoptosis and decreased
proliferation. Together, these data suggest that although telo-
mere dysfunctionmay enable cancer initiation, ongoing telomere
dysfunction and cellular checkpoints impede full malignant
progression of HPIN to invasive and metastatic disease, and
that activation of telomere maintenance mechanisms may be
needed to quell both rampant chromosomal instability and
residual cellular checkpoints. In this regard, it is notable that
there is no discernable inhibition in the progression from HPIN
to invasive disease in G2 mTert/ PB-Pten/p53 mice that do
not express telomerase yet maintain adequate telomere
reserves (data not shown). These data establish that telomerase
activity per se is not essential for prostate cancer progression,
providing tumor cells possess functional telomeres. Corre-
spondingly, current cell-based evidence in human and mouse
systems, together with the consistent expression of telomerase
in human prostate cancers (Kallakury et al., 1997; Lin et al., 1997;
Sommerfeld et al., 1996; Koeneman et al., 1998; Zhang et al.,
1998), supports the view that telomerase reactivation plays a crit-
ical role in overcoming apoptotic and proliferative blocks needed
for full malignant progression (Chang et al., 2003; Hahn et al.,
1999; Chin et al., 1999).
Here, our inducible telomerase model system enabled genetic
analysis of the impact of physiological endogenous telomerase
reactivation in a naturally arising solid tumor with short dysfunc-
tional telomeres. These studies established that telomerase
reactivation enabled rapidly progressive disease in all cases.
At the same time, we established that antecedent telomere
dysfunction enabled the acquisition of genomic events, including
those capable of endowing tumors with new biological proper-
ties such as bone metastasis, a phenotype not observed in G0
PB-Pten/p53 tumors (telomere intact). Thus, we conclude that
a period of telomere dysfunction is amechanism for the develop-
ment of chromosomal aberrations targeting genes involved in
prostate cancer development including bone metastasis.Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc. 903
The recurrent nature of amplifications and deletions of human
prostate cancer raised the possibility that, alongwith a handful of
known genetic lesions, there remain many uncharacterized
genes governing genesis and progression of this cancer (Taylor
et al., 2010). Beyond restoring genome stability and eliminating
DNA-damage signals, we and others have shown that genomic
alterations acquired in genome-unstable mouse tumor genomes
are not random, as they show statistical significant overlap
between mouse (which is telomerase deficient/unstable) and
human (which is telomerase reactivated) (Maser et al., 2007).
This observation leads us to hypothesize that reactivation of telo-
merase in the setting of pre-existing genome instability can be
a genomic mechanism for selection of cooperative events
required for ultimate progression—in other words, it is notmerely
a permissive step by removing DNA damage, but telomerase re-
activation is instead an active driver of progression. This study
provides formal genetic proof for this thesis. By triangulating
the list of genes resident in syntenic sCNAs in mouse and human
prostate cancers with biological phenotypes in human (e.g.,
documented bone metastasis), we have defined a prioritized
list of bone metastasis-associated genes. Pathway analysis
with this list revealed that the dominance of the TGF-b/SMAD4
network, coupled with the observation of spontaneously
acquired Smad4 genomic loss in two of the mouse tumors, led
to the hypothesis that SMAD4 inactivation is a driver for bone
metastasis in prostate cancers. Again, leveraging the power of
genetic engineering in the mouse, we went on to perform the
definitive genetic validation experiment proving the cooperativity
of p53/Pten/Smad4 codeletion in driving prostate tumorigenesis
and progression to bone metastasis in vivo.
It is, however, important to note that the penetrance of bone
metastasis in mice with triple inactivation of p53/Pten/Smad4
was far from 100%, suggesting that additional events beyond
Smad4 in the tumor and/or stromal cells can drive or are required
for bone metastasis. Indeed, many other candidates with likely
relevance have also been identified through our cross-species
comparative oncogenomic analysis. For example, among the
amplified genes, several have been implicated in cancer
progression. Metadherin (MTDH), a gene with dual activity to
promote metastasis and chemoresistance (Hu et al., 2009), is
overexpressed in human prostate cancer and known to act as
an activator of AKT and a suppressor of FOXO3a (Kikuno
et al., 2007). Protein tyrosine kinase 2 (PTK2, a.k.a., FAK), a
gene located in the frequently amplified 8q24 region, is well
known for its role in cell motility and proliferation (Chang et al.,
2007) and in promoting human prostate cancer cell invasiveness
(Johnson et al., 2008). Notable deleted genes include APC (20%
in human prostate cancer, 11% in mouse prostate cancer) and
Smad2/Smad4 (20% in human prostate cancer, 11% in mouse
prostate cancer), highlighting the importance of activation of
the Wnt signaling pathway and deactivation of the TGF-b
pathway in prostate cancer progression (Ding et al., 2011).
Lastly, because it is not likely that all of the evolutionarily
conserved candidates identified in this study represent true
drivers of prostate cancer progression in human, definitive
demonstration of biological activity and elucidation of mecha-
nisms of action for each will require significant downstream
activities by many. On the other hand, the prognostic signifi-904 Cell 148, 896–907, March 2, 2012 ª2012 Elsevier Inc.cance of the 14 pathway-representative genes is a strong correl-
ative support for functional veracity of the candidate list, even
thoughwe recognize that BCR is only a surrogate for aggressive-
ness of human prostate cancers. Further prognostic studies for
lethality will be necessarily to validate the true utility of the 14
gene signature in human.
In summary, this study provides in vivo genetic evidence
confirming the long-held hypothesis that telomerase reactivation
quells DNA-damage signaling and stabilizes the genome of an
initiated cancer to permit cancer progression. This study also
provides evidence in naturally occurring and initiated cancer
in vivo that telomere dysfunction followed by telomerase reacti-
vation serve as a mechanism for the generation of and selection
for cancer-relevant genomic alterations to drive progression and
new tumor biological hallmarks such as metastasis to bone.
Thus, telomerase serves as an active driver of cancer progres-
sion in the setting of telomere-based crisis. Furthermore, the
validation of telomere dysfunction as a relevant genome insta-
bility mechanism in prostate cancer, the generation of highly
rearranged genomeswith syntenic events, and the in silico docu-
mentation that altered genes are enriched for cancer relevance
collectively provide a system to enhance the mining of complex
human prostate cancer genomes to identify genetic events
governing prostate cancer progression.
EXPERIMENTAL PROCEDURES
mTert Knockout Allele and Pten and Trp53 (p53) Conditional Alleles
The mTert knockout allele and the PtenloxP conditional knockout alleles have
been described elsewhere (Zheng et al., 2008; Farazi et al., 2006). The p53loxP
strain was generously provided by A. Berns (Marino et al., 2000). Prostate
epithelium-specific deletion was effected by the PB-Cre4 (Wu et al., 2001)
andwasobtained fromMMHCC (http://mouse.ncifcrf.gov/search_results.asp).
Generation of the LSL-mTERTloxP Allele
We knocked an LSL cassette into the first intron of the mouse Tert gene (Fig-
ure 1A). The presence of the LSL cassette produces a nullmTert allele, and its
removal by PB-Cre expression restores activity under the control of the native
mTert promoter. This mouse model scheme allows for excellent specific
control of telomerase reconstitution in prostate epithelia cells. Following intro-
duction of the knockin construct into embryonic stem cells (ESCs), screening
ESCs, confirming germline transmission, and NeoR cassette deletion via
EIIa-Cre, the LSL-mTert allele was backcrossed four generations onto the
C57Bl/6 background.
Mating Scheme
As depicted in Figure S1, the LSL-mTertL/+ p53L/LPtenL/L mice were crossed
with G0 mTert+/p53L/LPtenL/LPB-Cre4 mice to generate G0 mTert+/p53L/L
PtenL/LPB-Cre4, G0 LSL-mTertL/+p53L/LPtenL/LPB-Cre4, G1 mTertLSL-
mTertLp53L/LPtenL/LPB-Cre4, and G1 mTertLSL-mTertLp53L/LPtenL/L mice.
These mice were then intercrossed to generate G2 mTert/p53L/LPtenL/L
PB-Cre4, G2 mTertLSL-mTertLp53L/LPtenL/LPB-Cre4, G2 LSL-mTertL/L
p53L/LPtenL/LPB-Cre4, G2 mTert/p53L/LPtenL/L, G2 mTert LSL-mTertL
p53L/LPtenL/L, G2 LSL-mTertL/Lp53L/LPtenL/L. G2 mice were then
intercrossed to generate G3 and G4 mice.
Tissue Analysis
Normal and tumor tissues were fixed in 10% neutral-buffered formalin
overnight, then processed, paraffin-embedded, sectioned, and stained with
hematoxylin and eosin (H&E) according to standard protocol. Immunohisto-
chemistry analysis was done as previously described (Ding et al., 2011).
Antibodies used for IHC include anti-Ki67 (Dako), anti-53BP1 (Bethyl Labs),
and anti-Cleaved Caspase 3 (Cell Signaling). Cells with the 53BP1 nuclear
punctuate foci were considered as 53BP1 positive, whereas the absence of
53BP1 nuclear foci signal was considered 53BP1 negative. Western blot
analysis was done as previously described (Ding et al., 2011).
Laser Capture Microdissection and DNA Extraction
Laser capture microdissection was done as previously described (Emmert-
Buck et al., 1996). Genomic DNA of microdissected prostate tumor cells
was extracted with phenol-chloroform prior to PCR analysis.
TUNEL Assay
To determine apoptosis in prostate tumor cells, TUNEL staining was per-
formed as previously described (Ding et al., 2011).
Cytogenetics, Quantitative Telomere-FISH, and Spectral
Karyotyping Analysis
We prepared metaphase chromosomes from early passage prostate tumor
cells as previously described (Maser et al., 2007).
Establishment of Mouse Prostate Tumor Cell Lines
Tumors were dissected from prostates of G0 PtenL/L Trp53L/LPB-Cre4+, G3,
and G4 mice. Cell lines were established as described previously (Ding
et al., 2011).
RNA Isolation and Real-Time PCR
Total RNA was extracted and real-time PCR were done as previously
described (Ding et al., 2011).
Array-CGH Profiling and Analysis of Mouse Prostate Tumors
Murine G3/4 LSL-mTert PB-Pten/p53 tumors were profiled against matched
normal tail DNA. Labeled DNAs were hybridized onto Agilent mouse 244K
CGH arrays, and scanning was performed per manufacturer’s protocol. Data
were processed using Agilent software. The array-CGH data of 18 G3/4
LSL-mTert PB-Pten/p53 tumorswere analyzed with theMCR algorithm (Maser
et al., 2007) to detect focal genomic regions with CNA events in at least two
tumors. Mouse genome data build mm9 was used in the analysis. A total of
2,183 genes from 57 amplified regions (Table S2) and 3,531 genes from 38
deletion regions were detected by the MCR algorithm.
Array-CGH Analysis with the GISTIC2 Algorithm for Recurrent Focal
and Arm-Level Chromosomal CNAs in Human Prostate Tumors
The array-CGH data of 194 human prostate tumors (Taylor et al., 2010) were
analyzed with the GISTIC2 algorithm (Beroukhim et al., 2007) to detect focal
genomic regions with CNA events. Focal regions with q values smaller than
0.25 are considered significant, which resulted in 16 amplified and 39 deleted
regions. Arm-level changes with q values smaller than 0.005 are considered
significant, which suggested chromosome 7p, 7q, and 8q amplification and
6q, 8p, 12p, 13q, 16q, 17p, and 18q deletion.
Homolog Mapping for CNA Synteny Regions Crosses Human
and Mouse Tumors
We used the NCBI homologene database (version 39.2) to map human and
mouse homolog genes and detect synteny CNA regions. The homologene
analysis characterized 300 amplified genes and 441 deleted genes that
commonly recurred in human and mouse prostate tumors.
Codeletion Analysis in Human Clinical Samples
Based on the results of theGISTIC2 analysis, 194 human prostate tumors (Tay-
lor et al., 2010) were classified into 4 groups according to PTEN and p53 focal
deletion status (Figure 5E). The numbers of SMAD4 deletion events in each
group were used to estimate by Fisher’s exact test in R environment the
significance p value of codeletion enrichment.
Correlation Analysis between Gene Copy Numbers and Gene
Expression Changes
The Spearman correlation coefficients between individual gene copy numbers
and expression levels in matching samples were calculated in R environment.
p values less than 0.05 were considered significant.Oncomine Consensus Analysis
Six prostate cancer cohorts (Holzbeierlein et al., 2004; Lapointe et al., 2004;
LaTulippe et al., 2002; Vanaja et al., 2003; Varambally et al., 2005; Yu et al.,
2004) in the Oncomine database (http://www.oncomine.com) were used to
filter our candidate marker gene lists. We tested the following hypotheses:
whether genes in the amplified regions are related to metastatic phenotypes
in any of the six cohorts, or whether genes in the deleted regions are related
to indolent phenotypes in any of the six cohorts.
Bone Metastasis-Related Copy Number Changes
We testedwhether genes recurrently amplified or deleted in thewhole prostate
cancer cohort of Taylor et al. showed consistent CNA patterns in tumors with
documented bone metastasis (Taylor et al., 2010). For each candidate gene,
we counted the numbers of gene gain (copy number > 0.3 in log2 scale) and
loss (copy number <0.3 in log2 scale) in 14 bone metastasis tumors. Consis-
tent changes are defined if an amplified CNA gene is more likely to have gain
than loss or a deleted CNA gene more likely to be lost than gained in bone
metastatic tumors.
Survival Analysis
We applied Cox proportional hazard regression on biomarkers of interest to
get a multivariate linear regression model that best predicts the biochemical
recurrence of prostate cancer. Tumors were subsequently divided into high-
risk and low-risk groups according to the scores. Kaplan-Meier curves were
plotted by R software, and the statistical significance was estimated by log-
rank test.
ACCESSION NUMBERS
Microarray and aCGH data were deposited in GEO (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE35247) under the accession number
GSE35247.
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